Henry J F, Denizot A, Puccini M, Niccoli P, Conte-Devolx B, de Micco C
Service de Chirurgie générale et endocrinienne, CHU Timone, Marseille.
Presse Med. 1996 Nov 2;25(33):1583-8.
Sporadic medullary cancer of the thyroid is often diagnosed late beyond the surgically curable stage. The aim of this work was to assess the capacity of routine calcitonin assay as an early diagnosis test for medullary cancer in patients with a thyroid lesion.
Calcitonin was assayed (normal < 10 pg/ml) as a routine test from 1993-1995 in a series of 2975 patients seen for thyroid exploration. When baseline level was above 10 pg/ml, a pentagastrine test was performed (normal < 30 pg/ml). All patients with a calcitonin peak > or = 100 pg/ml after pentagastrin underwent surgery for suspected medullary cancer. Surgery for suspected malignancy, hyperthyroidism or locoregional functional disorders was also performed in 1494 of the included patients, independent of calcitonin level. Patients with personal or familial history of multiple endocrine disease were excluded. Fine needle aspiration was done in all patients with an unique or predominant thyroid nodule.
Medullary cancer of the thyroid was demonstrated in 14 patients (0.47%). Among 8 patients with clinically patent tumor, the diagnosis was established in 3 on the basis of cytology results and elevated calcitonin level; in the 5 other cases, initial cytology was incorrect (anaplastic, papillary, thyroiditis) but correct diagnosis was established on the basis of high calcitonin levels. Diagnosis was suspected preoperatively in the 6 others solely because of high calcitonin; these patients had microlesions measuring 1.2-9 mm. None of the 7 patients with a medullary cancer measuring < 10 mm had node extension at surgery and all 7 attained biological cure. Among the 7 other patients with a lesion > 10 mm, calcitonin level returned to normal level in 3 and remained high in 2; the 2 others died with distant metastasis.
Routine assay of calcitonin in all patients with a thyroid nodule can improve preoperative diagnosis of medullary cancer of the thyroid and allows early diagnosis of latent infraclinical tumors.
散发性甲状腺髓样癌常常在超出手术可治愈阶段后才被诊断出来。本研究的目的是评估常规降钙素检测作为甲状腺病变患者髓样癌早期诊断检测方法的能力。
1993年至1995年期间,对一系列2975例因甲状腺探查而就诊的患者进行了降钙素检测(正常范围<10 pg/ml)作为常规检查。当基线水平高于10 pg/ml时,进行五肽胃泌素试验(正常范围<30 pg/ml)。所有五肽胃泌素刺激后降钙素峰值≥100 pg/ml的患者因疑似髓样癌接受手术。纳入的1494例患者中,无论降钙素水平如何,因疑似恶性肿瘤、甲状腺功能亢进或局部功能障碍也接受了手术。排除有个人或家族性多内分泌疾病史的患者。对所有有单个或主要甲状腺结节的患者进行细针穿刺。
确诊甲状腺髓样癌14例(0.47%)。在8例临床可触及肿瘤的患者中,3例根据细胞学结果和升高的降钙素水平确诊;在其他5例中,最初的细胞学诊断错误(未分化癌、乳头状癌、甲状腺炎),但根据高降钙素水平确诊。另外6例术前仅因降钙素水平高而怀疑诊断;这些患者有1.2 - 9 mm的微小病变。7例髓样癌直径<10 mm的患者在手术时均无淋巴结转移,且全部7例均实现生物学治愈。在另外7例病变>10 mm的患者中,3例降钙素水平恢复正常,2例仍高;另外2例死于远处转移。
对所有甲状腺结节患者进行常规降钙素检测可改善甲状腺髓样癌的术前诊断,并能早期诊断潜在的亚临床肿瘤。